Abstract:Introduction: Human myasthenia gravis (MG) is an autoimmune disorder of the neuromuscular system. Experimental autoimmune myasthenia gravis (EAMG) is a well-established animal model for MG that can be induced by active immunization with the Torpedo californica-derived acetylcholine receptor (AChR). Due to the expensive cost of purifying AChR from Torpedo californica, the development of an easier and more economical way of inducing EAMG remains critically needed. Material and methods: Full-length cDNA of the human skeletal muscle AChR α1 subunit was obtained from TE671 cells. The DNA fragment encoding the extracellular domain (ECD) was then amplified by polymerase chain reaction (PCR) and inserted into pET-16b. The reconstructed plasmid was transformed into the host strain BL21(DE3)pLysS, which was derived from Escherichia coli. Isopropyl-β-D-thiogalactopyranoside (IPTG) was used to induce the expression of the N-terminal ECD. The produced protein was purified with immobilized Ni(2+) affinity chromatography and refolded by dialysis. Results: The recombinant protein was efficiently refolded to soluble active protein, which was verified by ELISA. After immunization with the recombinant ECD, all rats acquired clinical signs of EAMG. The titer of AChR antibodies in the serum was significantly higher in the EAMG group than in the control group, indicating successful induction of EAMG. Conclusions: We describe an improved procedure for refolding recombinant ECD of human muscle AChR. This improvement allows for the generation of large quantities of correctly folded recombinant ECD of human muscle AChR, which provides for an easier and more economical way of inducing the animal model of MG.

Preparation of Single Chain Variable Fragment Gene in Myasthenia Gravis

Construction of Gene of Single Chain Variable Fragment Against Acetylcholine Receptor in Myasthenia Gravis

Fusion Protein of Single-Chain Variable Domain Fragments for Treatment of Myasthenia Gravis

Expression of Single Chain Variable Fragment A7 Gene in Myasthenia Gravis in Pichia Pastoris

Construction of the Fusion Gene of Single Chain Antibody Against Human Acetylcholine Receptor with Human Serum Albumin

Construction of Eukaryotic Expression Vector of Gene of Single Chain Variable Fragment A7

Cloning and Sequence Analysis of V_H and V_L Gene of Anti-Cd3 McAb

Suppressive Effect of the Single Chain Antibody Against Acetylcholine Receptor on the Binding Activity of the Pathogenic Antibodies

Potential Roles of Recombinant Acetylcholine Receptor Α Subunit 1–211 in Immunoadsorbent and DNA Immunization

Characterization of Expressed Anti-Cetylcholine Receptor Single Chain Variable Fragment in Pichia Pastoris

Construction and Characterization of a Human Anti-Acetylcholine Receptor Autoantibody

Artificial Construction of Human Pathogenic Autoantibody in Myasthenia Gravis

Construction and Expression of a Fusion Protein Containing Extracellular Domain of Human AChRα1 and Fc Fragment of Human IgG1

Construction of Eukaryotic Expression Vector of AChR-IgG Fc Fragment Fusion Protein and Its Expression in CHOk1 Cells

The cloning and expression of single-chain Fv antibody gene fragments against acetylcholine receptor

PATHOGENICITY AND SEQUENCE ANALYSIS OF A MOUSE MONOCLONAL ANTIBODY AGAINST HUMAN ACETYLCHOLINE RECEPTOR IN MYASTHENIA GRAVIS

Inhibition of Sera from Patients with Myasthenia Gravis to the Binding of Acetylcholine Receptor by a Fusion Protein of Antibody Fragment and Albumin

Protective effect of scFv-DAF fusion protein on the complement attack to acetylcholine receptor: a possible option for treatment of myasthenia gravis.

Construction of a myasthenia gravis model by immunizing mice with gene vaccine pcDNA-AChR_(α211)

Improved methodology to obtain large quantities of correctly folded recombinant N-terminal extracellular domain of the human muscle acetylcholine receptor for inducing experimental autoimmune myasthenia gravis in rats

[Cloning and Sequencing of VL and VH Genes from a Novel Clone ZCH-7-2F9 of Anti-Hcd14 Monoclonal Antibody].